Therapeutic angiogenesis: Potential role of basic fibroblast growth factor in patients with severe ischaemic heart disease

BioDrugs

Volumn 14, Issue 1, 2000, Pages 13-20

  Simons, Michael ^a   Laham, Roger J ^a   Post, Mark ^a   Sellke, Frank W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; HEPARIN; NITRIC OXIDE; PLACEBO; VASCULOTROPIN;

ACUTE HEART INFARCTION; ANGIOGENESIS; ANIMAL MODEL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; HUMAN; HYPOTENSION; INTRACORONARY INFUSION; INTRAMYOCARDIAL DRUG ADMINISTRATION; INTRAPERICARDIAL DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; NEPHROTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

EID: 0033870778     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200014010-00002     Document Type: Review

References (61)

1. Fibroblast growth factors: At the heart of angiogenesis
2. Clinical applications of angiogenic growth factors and their inhibitors
3. Role of platelet-derived growth factors in angiogenesis and alveogenesis
4. The angiopoietins: Yin and Yang in angiogenesis
5. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
6. PR39, A peptide regulator of angiogenesis
7. Angiogenesis in ischemic heart disease
8. Fibroblast growth factors and their receptors
9. Heparan sulfate proteoglycans of the cardiovascular system
10. Isolation, characterization, and localization of heparin-binding growth factors in the heart
11. Generation and localisation of monoclonal antibodies against fibroblast growth factors in ischaemic collateralised porcine myocardium
12. Fibroblast growth factor 2 control of vascular tone
13. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix: Role of urokinase activity
14. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels
15. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro
16. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo
17. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells: Synergistic interaction with hypoxia
18. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: An autocrine mechanism contributing to angiogenesis
19. The role of syndecan cytoplasmic domain in basic fibroblast growth factor-dependent signal transduction
20. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor
21. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium
22. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model
23. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury
24. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts
25. Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: A comparison of angiographic, echocardiographic and coronary flow parameters
26. Modulation of myocardial perfusion and vascular reactivity by pericardial basic fibroblast growth factor: Insight into ischemia-induced reduction in endothelium-dependent vasodilatation
27. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia
28. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
29. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1
30. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor
31. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs
32. Vascular endothelial growth factor administration in chronic myocardial ischemia
33. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts
34. Comparison of VEGF delivery techniques on collateral-dependent microvascular reactivity
35. VEGF administration in chronic myocardial ischemia in pigs
36. Perivascular and intravenous administration of basic fibroblast growth factor: Vascular and solid organ deposition
37. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a phase I randomized, double-blind, placebo-controlled trial
38. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes
39. Subxyphoid access of the normal pericardium: A novel drug delivery technique
40. Basic FGF enhances endothelium-dependent relaxation of the collateral-perfused coronary microcirculation
41. Intracoronary and intravenous administration of basic fibroblast growth factor: Myocardial and tissue distribution
42. Therapeutic angiogenesis with basic fibroblast growth factor: Technique and early results
43. Intracoronary administration of recombinant fibroblast growth factor-2 (rFGF-2) in patients with severe coronary artery disease: Results of phase I
44. Double blind placebo controlled trial of recombinant human vascular endothelial growth factor-the VIVA trial
45. Preclinical and clinical studies with recombinant human basic fibroblast growth factor
46. Local perivascular administration of basic fibroblast growth factor: Drug delivery and toxicological evaluation
47. Hypotensive activity of fibroblast growth factor
48. Hemodynamic effects of intracoronary VEGF delivery: Evidence of tachyphylaxis and NO dependence of response
49. Vascular endothelial growth factor (VEGF) affects microvessels but not epicardial arteries and veins
50. Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factor-2
51. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development
52. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat-angiogenesis and angioma formation
53. Vascular response to basic fibroblast growth factor when infused onto the normal adventitia or into the injured media of the rat carotid artery
54. Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries
55. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo
56. Angiogenic processes in the pathogenesis of human coronary atherosclerosis
57. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice
58. Angiogenesis in human coronary atherosclerotic plaques
59. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy
60. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
61. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins